About this Journal Submit a Manuscript Table of Contents
Journal of Ophthalmology
Volume 2013 (2013), Article ID 268438, 7 pages
http://dx.doi.org/10.1155/2013/268438
Clinical Study

Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab

1Department of Optometry, School of Physics, Dublin Institute of Technology, Dublin, Ireland
2Institute of Eye Surgery and Institute of Vision Research, Whitfield Clinic, Waterford, Ireland
3Macular Pigment Research Group, Waterford Institute of Technology, Waterford, Ireland
4African Vision Research Institute, Faculty of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
5NH & MRC Centre for Clinical Eye Research, Department of Optometry and Vision Science, Flinders Medical Centre & Flinders University of South Australia, Bedford Park, Australia

Received 24 October 2012; Accepted 23 January 2013

Academic Editor: Chi-Chao Chan

Copyright © 2013 Sarah Sabour-Pickett et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. A. Bhutto, D. S. McLeod, T. Hasegawa et al., “Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration,” Experimental Eye Research, vol. 82, no. 1, pp. 99–110, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Wong, U. Chakravarthy, R. Klein et al., “The Natural History and Prognosis of Neovascular age-related macular degeneration. A Systematic Review of the Literature and Meta-analysis,” Ophthalmology, vol. 115, no. 1, pp. 116.e1–126.e1, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. R. N. Frank, R. H. Amin, D. Eliott, J. E. Puklin, and G. W. Abrams, “Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes,” American Journal of Ophthalmology, vol. 122, no. 3, pp. 393–403, 1996. View at Scopus
  4. A. Kvanta, P. V. Algvere, L. Berglin, and S. Seregard, “Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor,” Investigative Ophthalmology and Visual Science, vol. 37, no. 9, pp. 1929–1934, 1996. View at Scopus
  5. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Owsley, “Contrast sensitivity,” Ophthalmology Clinics of North America, vol. 16, no. 2, pp. 171–177, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. G. S. Rubin, K. Bandeen-Roche, G. H. Huang et al., “The association of multiple visual impairments with self-reported visual disability: SEE project,” Investigative Ophthalmology and Visual Science, vol. 42, no. 1, pp. 64–72, 2001. View at Scopus
  9. K. R. Koch, P. S. Muether, M. M. Hermann, R. Hoerster, B. Kirchhof, and S. Fauser, “Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, pp. 201–209, 2012.
  10. B. Feigl, A. Greaves, and B. Brown, “Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity,” Journal of Clinical Ophthalmology, vol. 1, pp. 167–175, 2007.
  11. D. S. Loshin and J. White, “Contrast sensitivity. The visual rehabilitation of the patient with macular degeneration,” Archives of Ophthalmology, vol. 102, no. 9, pp. 1303–1306, 1984. View at Scopus
  12. M. A. Sandberg and A. R. Gaudio, “Slow photostress recovery and disease severity in age-related macular degeneration,” Retina, vol. 15, no. 5, pp. 407–412, 1995. View at Scopus
  13. M. Parravano, F. Oddone, M. Tedeschi et al., “Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results,” Retina, vol. 30, no. 7, pp. 1017–1024, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. C. G. Kiss, W. Geitzenauer, C. Simader, G. Gregori, and U. Schmidt-Erfurth, “Evaluation of ranibizumab-induced changes in high- resolution optical coherence tomographic retinal morphology and their impact on visual function,” Investigative Ophthalmology and Visual Science, vol. 50, no. 5, pp. 2376–2383, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Midena, P. P. Radin, E. Pilotto, A. Ghirlando, E. Convento, and M. Varano, “Fixation pattern and macular sensitivity in eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. A Microperimetry Study,” Seminars in Ophthalmology, vol. 19, no. 1-2, pp. 55–61, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Ozdemir, M. Karacorlu, F. Senturk, S. A. Karacorlu, and O. Uysal, “Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration,” Acta Ophthalmologica, vol. 90, pp. 71–75, 2012.
  17. R. Das, Y. Shi, G. Silvestri, and U. Chakravarthy, “Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to lucentis therapy,” Retina, vol. 29, no. 7, pp. 1013–1018, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Ergun, N. Maár, W. Radner, I. Barbazetto, U. Schmidt-Erfurth, and M. Stur, “Scotoma size and reading speed in patients with subfoveal occult choroidal neovascularization in age-related macular degeneration,” Ophthalmology, vol. 110, no. 1, pp. 65–69, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Stifter, H. Weghaupt, T. Benesch, A. Thaler, and W. Radner, “Discriminative power of reading tests to differentiate visual impairment caused by cataract and age-related macular degeneration,” Journal of Cataract and Refractive Surgery, vol. 31, no. 11, pp. 2111–2119, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Kloos, P. Bernasconi, S. Estermann, B. Bachmann, Y. Rutishauser, and A. Thölen, “Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration,” Klinische Monatsblatter fur Augenheilkunde, vol. 225, no. 5, pp. 385–391, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. T. S. Chang, N. M. Bressler, J. T. Fine, C. M. Dolan, J. Ward, and T. R. Klesert, “Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial,” Archives of Ophthalmology, vol. 125, no. 11, pp. 1460–1469, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. I. J. Suńer, G. T. Kokame, E. Yu, J. Ward, C. Dolan, and N. M. Bressler, “Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials,” Investigative Ophthalmology and Visual Science, vol. 50, no. 8, pp. 3629–3635, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. E. L. Lamoureux, P. Mitchell, G. Rees et al., “Impact of early and late age-related macular degeneration on vision-specific functioning,” British Journal of Ophthalmology, vol. 95, pp. 666–670, 2011.
  24. R. P. Singh, E. X. Fu, S. D. Smith, D. R. Williams, and P. K. Kaiser, “Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age-related macular degeneration: an optical coherence tomography study,” British Journal of Ophthalmology, vol. 93, no. 10, pp. 1353–1358, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. K. Kaiser, D. M. Brown, K. Zhang et al., “Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results,” American Journal of Ophthalmology, vol. 144, no. 6, pp. 850.e4–857.e4, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. G. A. Lalwani, P. J. Rosenfeld, A. E. Fung et al., “A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study,” American Journal of Ophthalmology, vol. 148, no. 1, pp. 43–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Hohberger, R. Laemmer, W. Adler, A. G. M. Juenemann, and F. K. Horn, “Measuring contrast sensitivity in normal subjects with OPTEC 6500: influence of age and glare,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 245, no. 12, pp. 1805–1814, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Rohrschneider, C. Springer, S. Bültmann, and H. E. Völcker, “Microperimetry—comparison between the micro perimeter 1 and scanning laser ophthalmoscope—fundus perimetry,” American Journal of Ophthalmology, vol. 139, no. 1, pp. 125–134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Stifter, F. König, T. Lang et al., “Reliability of a standardized reading chart system: variance component analysis, test-retest and inter-chart reliability,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 242, no. 1, pp. 31–39, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Massin, E. Vicaut, B. Haouchine, A. Erginay, M. Paques, and A. Gaudric, “Reproducibility of retinal mapping using optical coherence tomography,” Archives of Ophthalmology, vol. 119, no. 8, pp. 1135–1142, 2001. View at Scopus
  31. J. Loughman, M. C. Akkali, S. Beatty et al., “The relationship between macular pigment and visual performance,” Vision Research, vol. 50, no. 13, pp. 1249–1256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. D. M. Brown, M. Michels, P. K. Kaiser, J. S. Heier, J. P. Sy, and T. Ianchulev, “Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study,” Ophthalmology, vol. 116, no. 1, pp. 57–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. A. E. Fung, G. A. Lalwani, P. J. Rosenfeld et al., “An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration,” American Journal of Ophthalmology, vol. 143, no. 4, pp. 566–583, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. P. K. Kaiser, B. A. Blodi, H. Shapiro, and N. R. Acharya, “Angiographic and optical coherence tomographic results of the MARINA Study of ranibizumab in neovascular age-related macular degeneration,” Ophthalmology, vol. 114, no. 10, pp. 1868–1875, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. T. A. Williams and C. P. Blyth, “Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12,” Eye, vol. 25, pp. 1617–1621, 2011.
  36. J. Monés and G. S. Rubin, “Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration,” Eye, vol. 19, no. 11, pp. 1142–1150, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. I. U. Scott, W. J. Feuer, and J. A. Jacko, “Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration,” American Journal of Ophthalmology, vol. 133, no. 3, pp. 350–357, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. G. S. Rubin, K. B. Roche, P. Prasada-Rao, and L. P. Fried, “Visual impairment and disability in older adults,” Optometry and Vision Science, vol. 71, no. 12, pp. 750–760, 1994. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Kuyk and J. L. Elliott, “Visual factors and mobility in persons with age-related macular degeneration,” Journal of Rehabilitation Research and Development, vol. 36, no. 4, pp. 303–312, 1999. View at Scopus
  40. M. Varano and C. Scassa, “Scanning laser ophthalmoscope microperimetry,” Seminars in Ophthalmology, vol. 13, no. 4, pp. 203–209, 1998. View at Scopus
  41. P. Alexander, F. Mushtaq, C. Osmond, and W. Amoaku, “Microperimetric changes in neovascular age-related macular degeneration treated with ranibizumab,” Eye, vol. 26, pp. 678–683, 2012.
  42. C. Frennesson, U. L. Nilsson, B. B. Peebo, and S. E. G. Nilsson, “Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration,” Acta Ophthalmologica, vol. 88, no. 4, pp. 420–425, 2010. View at Publisher · View at Google Scholar · View at Scopus